Rezolute, Inc. (RZLT)
| Market Cap | 127.21M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -18.87M |
| Shares Out | 5.87M |
| EPS (ttm) | -3.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $15.23 |
| Previous Close | $14.60 |
| Change ($) | 0.63 |
| Change (%) | 4.32% |
| Day's Open | 14.21 |
| Day's Range | 14.15 - 15.23 |
| Day's Volume | 3,499 |
| 52-Week Range | 11.99 - 20.99 |
News
There are no news available yet.
About RZLT
Rezolute, a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also develops RZ402, a small molecule plasma kallikrein inhibitor, which is in preclinical stage for the treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rez... [Read more...]
| Industry Biotechnology | Founded 2010 |
| CEO Nevan Elam | Employees 23 |
| Stock Exchange NASDAQ | Ticker Symbol RZLT |
Analyst Forecasts
According to 2 analysts, the average rating for Rezolute stock is "Buy." The 12-month stock price forecast is 31.50, which is an increase of 106.83% from the latest price.